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Differentiated THP1 cellPhospholipid transfer protein (PLTP) plays an important role in regulation of inﬂammation. Previously
published studies have shown that PLTP binds, transfers and neutralizes bacterial lipopolysaccharides. In the
current study we tested the hypothesis that PLTP can also regulate anti-inﬂammatory pathways in
macrophages. Incubation of macrophage-like differentiated THP1 cells and human monocyte-derived
macrophages with wild-type PLTP in the presence or absence of tumor necrosis factor alpha (TNFα) or
interferon gamma (IFNγ) signiﬁcantly increased nuclear levels of active signal transducer and activator of
transcription 3, pSTAT3Tyr705 (pb0.01). Similar results were obtained in the presence of a PLTP mutant
without lipid transfer activity (PLTPM159E), suggesting that PLTP-mediated lipid transfer is not required for
activation of the STAT3 pathway. Inhibition of ABCA1 by chemical inhibitor, glyburide, as well as ABCA1 RNA
inhibition, reversed the observed PLTP-mediated activation of STAT3. In addition, PLTP reduced nuclear levels
of active nuclear factor kappa-B (NFκB) p65 and secretion of pro-inﬂammatory cytokines in conditioned
media of differentiated THP1 cells and human monocyte-derived macrophages. Our data suggest that PLTP
has anti-inﬂammatory capabilities in macrophages.sporter A1; IFNγ, interferon
e-2; LPS, lipopolysaccharides;
, nuclear factor kappa-B; PLTP,
tate 13-acetate; STAT3, signal
binding protein; TGFβ, tumor
r necrosis factor alpha
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Macrophages are the key immune cells in organs and tissues, are
involved in the innate immune response, and play a critical role in
both initiation and resolution of inﬂammation. Activation of the
macrophage-dependent immune response is of decisive importance
in acute infections. However, prolonged activation of macrophages
associated with chronic disease is often detrimental, and contributes
to the pathophysiological processes of numerous chronic diseases,
including atherosclerosis, chronic kidney disease and diabetes.
Therefore, understanding the physiological and pathophysiological
processes that regulate themacrophage-dependent immune responseis a signiﬁcant element in the formulation of novel prophylactic and
therapeutic approaches for many chronic diseases.
Phospholipid transfer protein (PLTP) is a versatile, widely expressed
protein involved in transport of lipids and vitamin E among lipoproteins,
and between lipoproteins and cells. Reported functional roles of PLTP
include participation in reverse cholesterol transfer, lipoprotein metab-
olism, inﬂammatory processes, signal transduction, cell differentiation
and apoptosis [1–8]. PLTP levels and activity are signiﬁcantly altered in
numerous human diseases and conditions with a strong inﬂammatory
component, such as atherosclerosis, diabetes, and neuroinﬂammatory
diseases [9–16]. These reports suggest that PLTP may be playing an
important role in the regulation of inﬂammatory processes, although the
mechanisms of PLTP actions are currently poorly understood.
PLTP is expressed in macrophages in both normal and atherogenic
blood vessels [9,17,18]. Recent reports suggest that macrophage-
derived PLTP plays an important role in atherosclerosis [19,20].
However, the interplay between macrophages and PLTP is inade-
quately understood. The macrophage-dependent immune response is
regulated by signal transduction pathways dependent on extracellular
ligands and other pathway components that activate or inactivate
signal transduction processes. We previously reported that PLTP
interacts with the ATP-binding cassette A1 (ABCA1) to enhance
cholesterol efﬂux from cells, and that PLTP's interaction with ABCA1
activates Janus kinase-2, JAK2 [21,22]. In this study we provide
evidence that PLTP activates STAT3, and inhibits NFκB inmacrophage-
like THP1 cells and in human monocyte-derived macrophages.
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2.1. Antibodies, cells, and materials
Antibodies against phosphorylated JAK2 (Cat. No. 3771), STAT3
(Cat. No. 4904), STAT3 phosphorylated at tyrosine 705 (Cat. No.
9131), NFκB p65 total and phosphorylated at serine 536 (Cat. Nos.
3034 and 3033, respectively), IL1β (Cat. No. 2022), TGFβ (Cat. No.
3711), and human TNFα (Cat. No. 2169) were obtained from Cell
Signaling Technology (Danvers, MA). Antibody against JAK2 was
obtained from Santa Cruz Biotechnologies (Cat. No. SC-34479-R)
TATA-binding protein (TBP) and MIP1α antibodies (Cat. Nos. 62125;
and ab0381, respectively) were from Abcam (Cambridge, MA). Anti-
IL6 (Cat. No. AF-206-NA) and anti-IL10 antibodies (Cat. No. AF-217-
NA), as well as IL1β, MIP1α and TGFβ ELISA plates (Cat. Nos. HSLB00C,
DMA00 and DB100B, respectively) were purchased from R&D Systems
(Minneapolis, MN). Antibody against β-actin (Cat. No. A2066),
interferon gamma (IFNγ; Cat. No. I32265), PMA (Cat. No. P8139)
and glyburide (Cat. No. G2569) were from Sigma-Aldrich (St. Louis,
MO). Secondary antibodies, anti-rabbit, anti-mouse and anti-goat
TrueBlot (Cat. Nos. 18-8816; 18-8817; and 18-8814, respectively),
and recombinant human M-CSF and GM-CSF (Cat. Nos. 14-8789 and
14-8339, respectively) were from eBioscience Inc. (San Diego, CA).
Human ABCA1 shRNA Mission lentiviral transduction particles and
control Mission pLKO.1-puro transduction particles were from Sigma-
Aldrich St. Louis, MO (Cat. Nos. SHCLNV-NM_005502 and SHC001V,
respectively), as well as puromycin (Cat. No. P9620). Protein isolation
kit, NE-PER, HALT protease inhibitor cocktail, Detoxi-Gel endotoxin
removing column (Cat. No. 20344) and SuperSignal West
Femto maximum sensitivity substrate were obtained from Thermo
Scientiﬁc/Pierce Biotechnology (Rockford, IL). Phosphatase inhibitor
cocktail (Cat. No. 524627) and PhosphoSafe protein isolation solution
were purchased from Calbiochem-EMD BioSci (La Jolla, CA). Criterion
XT gels, MOPS buffer and XT sample buffer were obtained from Bio-
Rad (Hercules, CA). PhosphoBlocker blocking reagent (Cat. No. AKR-
104) was from Cell Biolabs (San Diego, CA). Humanmononuclear cells
PBMC (Cat. No. 1001) were procured from Astarte Biologics
(Redmond, WA). Specialized macrophage medium, macrophage-
SFM, was purchased from Invitrogen (Carlsbad, CA). RPMI-1640
media, L-glutamine, non-essential amino-acids, and trypsin–
versene were obtained from Lonza Biosciences (Walkersville, MD).
Nutridoma-SP (Cat. No. 11011375001) was from Roche Applied
Science (Indianapolis, IN). Characterized fetal bovine serum with
endotoxin levels below biologically signiﬁcant concentration was
acquired from Thermo Fisher Scientiﬁc/Hyclone (Logan, UT). [C14]-
labeled phosphatidylcholine was purchased from Perkin Elmer Life
Sci. Pyrochrome Limulus polyphemus Amoebocyte Lysate (LAL) kit
(Cat. No. C1500), endotoxin standards (E. coli O113-H10; Cat. No.
EC010), LAL reagent water, Pyroplate microplates, endotoxin-free
pipette tips and borosilicate glass tubes were from the Associates of
Cape Cod Inc. (East Falmouth, MA). Multiplex kits for human
cytokines and chemokines were purchased from Linco Research (St.
Charles, MO) and Bio-Rad (Hercules, CA). Recombinant wild-type and
mutant PLTP were expressed and isolated as previously reported
[1,23].
2.2. Cell culture
The human monocytic leukemia cell line THP1 (ATCC Cat. No. TIB-
202) was grown in RPMI media supplemented with 10% fetal bovine
serum or Nutridoma, at 37 °C in 5% CO2. No differences were observed
in cells grown with Nutridoma compared to serum supplementation
(not shown). THP1 cells in suspension were seeded at equal density
into multiwell plates, differentiated into macrophage-like cells by
addition of PMA (1.6×10−7 M) for 72 h, and then used in experi-
ments. These THP1 cells were pre-incubated with PLTP (5 μg/ml) for4 h, extensively washedwith PBS, and then exposed to either 100 ng/ml
LPS, 10 ng/ml IFNγ, or 100 ng/ml TNFα for up to 24 h. Similar studies
were performed using co-incubation protocols. In time-dependent
studies for both modalities (pre- and co-incubation) the optimal time
for our experiments was evaluated. Chosen protocols were conﬁrmed
by experiments under identical conditions using fully developed human
monocyte-derived macrophages 8 days after attachment, which had
been grown in Macrophage-SFMmedium, supplemented with GM-CSF.
The cells were pre-incubated with PLTP in SFM medium for 4 h,
extensively washed and then incubated for up to 24 h with TNFα. The
resulting conditioned media had reduced IL-1β levels, indicating that
pre-incubation of human monocyte-derived macrophages with PLTP
reduces secretion of pro-inﬂammatory cytokines similar to THP1 cells
(see Results), thus validating our cell culture data obtained in the THP1
cell line. All cell culture experiments were performed in triplicate for
each condition, and repeated at least three times to conﬁrm our results.2.3. ABCA1 RNA inhibition
Inhibition of ABCA1 expression in THP1 cells was performed using
human ABCA1 shRNA Mission lentiviral transduction particles (ﬁve
constructs: TRCN0000029089, TRCN0000029090, TRCN0000029091,
TRCN0000029092 and TRCN0000029093) and control Mission
pLKO.1-puro transduction particles (Sigma-Aldrich, St. Louis, MO).
We initially established the concentration of the selection agent
(puromycin) required to kill 100% of THP1 cells. Cells were incubated
for 48 h in growth medium without (control) or with puromycin
(0.1–1 μg/ml). Cell survival was assessed by Trypan blue. All cells
were dead in the presence of 0.6 μg/ml of puromycin, and this
concentration of puromycin was used in the selection protocol.
Transduction of THP1 cells was performed by spinoculation
(transduction by centrifugation; modiﬁed from [24]). THP1 cells
(3×105 cells/ml) grown in suspension in RPMI medium supplemen-
ted with 10% FBS were placed in sterile conical 15 ml tubes (6 tubes;
2 ml of cells in each tube). Lentiviral particles (11 μl/ml of cells) were
added to the cells and centrifuged at 1000 ×g, 28 °C for 1 h. Medium
containing lentiviral particles was aspirated, cells mixed with fresh
growth medium (RPMI, 10% FBS) and placed in a 6-well plate. Cells
were incubated at 37 °C, 5% CO2, 95% humidity for 48 h. Following
incubation, the spinoculation was repeated and cells placed in
puromycin-containing medium (0.6 μg/ml) for selection of clones
containing puromycin-resistant constructs. Control THP1 cells were
subjected to the same procedure, but without exposure to the virus or
puromycin. Cell viability was tested after 48 h, and all samples
contained viable cells. Clones were expanded in the presence of
puromycin, and tested for ABCA1 by qRT-PCR and Western blotting.
Based on these studies, THP1 cells in which ABCA1 was inhibited with
construct TRCN0000029089 were selected for analysis.
Following successful transduction, spinoculation control THP1
cells, THP1 cells containing control (mock) or ABCA1 shRNA construct
were incubated with PMA for 72 h in the presence of puromycin.
Adherent THP1 macrophages were used for evaluation of the PLTP
effect on activation of STAT3.2.4. Protein isolation
Cytoplasmic and nuclear proteins were isolated using the NE-PER
kit according to the manufacturer's instructions, with addition of
phosphatase inhibitor cocktail to preserve phosphorylated proteins.
Membrane proteins were isolated using MEM-PER kit according to
the manufacturer's instructions. Whole cell lysates were prepared
using PhosphoSafe protein isolation solution, according to the
manufacturer's instructions. Samples were evaluated for total protein
concentration, and aliquots stored at −70 °C until analysis.
Fig. 1. PLTP activates Janus kinase 2 (JAK2) in THP1 macrophages. THP1 cells were
differentiated using PMA for 72 h and incubated without or with PLTP (5 μg/ml) for
30 min. Isolated protein was immunoprecipitated using antibody against JAK2 and
blotted against phosphorylated and total JAK2.
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THP1 cells were lysed in Tris–HCl buffer (50 mM Tris–HCl, pH 7.4,
120 mM NaCl, 1% Nonidet P40) supplemented with protease in-
hibitors (Complete mini; Roche) and phosphatase inhibitors (phos-
phatase inhibitor cocktail II; Calbiochem) and then centrifuged at
15,000 ×g for 10 min at 4 °C. Protein concentration was measured
using the Bio-Rad protein assay reagent as instructed. For immuno-
precipitation, 100 μg of lysates was incubated with the indicated
JAK2 antibody (2–4 μg) overnight at 4 °C followed by incubation for
1 h with Protein A-magnetic beads (Invitrogen, Dynabeads protein A).
Immunocomplexes were resolved by SDS-PAGE and immunoblotted
with phospho-JAK2 (Cell Signaling), then stripped and re-probedwith
JAK2 antibodies.
2.6. Electrophoresis, Western blot
Proteins were isolated using PhosphoSafe protein isolation
solution, which preserves phosphorylated sites in the presence of
protease inhibitors (Halt protease inhibitor cocktail, Invitrogen),
according to the manufacturer's instructions. Cell proteins were
subjected to denaturing sodium-dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blot analysis as follows:
samples were loaded on 4–12% gel (Bis–Tris Criterion XT), and
following electrophoresis, transferred to nitrocellulose or PVDF
membrane using Bio-Rad wet or semi-dry transfer. Blots were
incubated overnight with primary antibodies at 4 °C with agitation
in PBS with 5% PhosphoBlocker, a specialized blocker that preserves
availability of phosphorylated sites for antibody binding, or with dry
milk (the same blocker was used in all incubation steps). Protein
loading was controlled by using β-actin (cytoplasmic) or TBP (nuclear
proteins). The membranes were incubated with the appropriate
TrueBlot secondary antibody for 2 h at room temperature. The blots
were developed usingWest Femto SuperSignal chemiluminescent kit,
scanned on a Kodak CF400 imaging system, and evaluated by
densitometry scanning.
2.7. PLTP activity assay
Phospholipid transfer activity of PLTP was performed as reported
[25]. One hundred microliters of conditioned cell culture medium
per sample was used to measure transfer of radioactively-labeled
phosphatidylcholine ([C14]PC) to a high density lipoprotein (HDL)
acceptor. Triplicate samples were analyzed in triple technical
replicates, and counted in Beckman-Coulter LS6500 scintillation
counter three times. Samples were held frozen at −70 °C until
analysis, and each sample was thawed only once.
2.8. Limulus Amoebocyte Lysate, LAL assay
All materials employed in our experiments, including rPLTP, media
and sera, were tested with the LAL assay to conﬁrm that the observed
ﬁndings are not due to the known PLTP-mediated inactivation of
bacterial lipopolysaccharides, LPS [1,26]. The assay was performed
according to the manufacturer's instructions. The endotoxin levels in
all of the abovewere below biologically relevant LPS levels (b0.05 EU/ml
or b0.03 EU/μg of rPLTP).
2.9. Multiplex analyses
Levels of secreted cytokines in conditioned media were assessed
by Bio-Plex System Luminex xMAP technology (Bio-Rad) using Bio-
Rad and Linco plates. Two hundred microliters of conditioned media
were incubated in wells containing beads labeled with antibodies
against multiple pro-inﬂammatory markers, including IL1α, IL1β,
IL1ra, IL6, GM-CSF, TGFα, TNFα, MIP1α, interferon gamma (IFNγ),and VEGF. Triplicate samples for each condition were assayed in triple
replicates, and multiple analyses were performed using the same
samples. Positive results were conﬁrmed by Western blotting or
ELISA.
2.10. ELISA
Levels of IL1β, MIP1α and TGFβ in conditioned media were
assessed by commercial ELISA kits according to the manufacturer's
instructions (R&D Systems).
2.11. Statistical analyses
Statistical analyses were performed with Statistica for Windows
(StatSoft Inc., 2000, Tulsa, OK), using t-test, Mann–Whitney U test and
Wilcoxon matched pair test, and p-valuesb0.05 were considered
statistically signiﬁcant.
3. Results
3.1. PLTP induces activation of STAT3 in macrophage-like THP1 cells and
primary human monocyte-derived macrophages
We have previously shown that PLTP activates JAK2 in J774
macrophages [22]. In this studywe conﬁrm that PLTP activates JAK2 in
THP1 cells as well (Fig. 1).
To test whether PLTP induces activation of STAT3 in macrophages,
we incubated THP1 cells without or with PLTP, and evaluated nuclear
levels of STAT3 phosphorylated at tyrosine 705 (pSTAT3Tyr705), the
active form of STAT3 (Fig. 2A) [27–29]. Addition of PLTP signiﬁcantly
increased levels of pSTAT3Tyr705 in nuclei of THP1 cells, suggesting
that PLTP induces activation of STAT3. Similar effects were observed
in human monocyte-derived macrophages (Fig. 2B).
3.2. PLTP reverses pro-inﬂammatory action of IFNγ and TNFα on nuclear
levels of pSTAT3Tyr705 in differentiated THP1 cells and human monocyte-
derived macrophages
Following the above ﬁndings, we evaluated effects of PLTP on
IFNγ-induced inactivation of STAT3. Addition of PLTP reversed IFNγ-
induced reduction of pSTAT3Tyr705 nuclear levels (Fig. 2C). Similar
results were obtained in human monocyte-derived macrophages
incubated with tumor necrosis factor alpha (TNFα) (Fig. 2D).
3.3. PLTP effect on intranuclear levels of active STAT3 does not depend on
PLTP phospholipid transfer ability
We evaluated whether PLTP-mediated lipid transfer is required for
the observed increase in levels of active STAT3 in the nucleus. We
PLTP (5 µg/ml) - +      
C C WT M WT M
TNFα (ng/ml) 0 10 0 0 10 10







Fig. 2. PLTP increases levels of nuclear pSTAT3Tyr705 and reverses IFNγ- and TNFα-
mediated reduction of nuclear levels of pSTAT3Tyr705 in THP and human monocyte-
derived macrophages. A) THP1 cells were differentiated into macrophages through
PMA exposure for 72 h, and incubated without (control) or with PLTP (5 μg/ml) for 3 h;
proteins were isolated using NE-PER kit (Pierce); pSTAT3Tyr705 levels in nuclear
proteins were assessed by Western blotting and densitometry measurements adjusted
for TATA-binding protein, TBP. Bars represent mean and SD. B) Mature human
monocyte-derived macrophages were incubated in the presence or absence of PLTP for
3 h; proteins were isolated using NE-PER kit (Pierce); pSTAT3Tyr705 levels in nuclear
fraction were assessed by Western blotting. C) Following PMA-mediated differentia-
tion, THP1 cells were incubated without (control) or with interferon gamma (IFNγ,
100 ng/ml), alone or with PLTP (5 μg/ml). Nuclear levels of pSTAT3Tyr705 were assessed
by Western blotting and densitometry measurements adjusted for TBP. Bars represent
mean, SD. D) PLTP wild type (WT) or mutant (M = PLTPM159E) have similar effect on
intranuclear levels of pSTAT3Tyr705, suggesting that PLTP-mediated increase of nuclear
pSTAT3Tyr705 is not dependent on PLTP's lipid transfer ability. PMA-differentiated THP1
cells were incubated without or with TNFα, in the presence or absence of WT or mutant
(without phospholipid transfer activity) PLTP (PLTPM159E). Nuclear pSTAT3Tyr705 levels
were assessed by Western blotting. TATA-binding protein (TBP) was used as loading
control.
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without phospholipid transfer activity (PLTPM159E) [22]. Our results
indicate that the PLTP-mediated increase in nuclear pSTAT3Tyr705 is
not dependent on PLTP's phospholipid transfer activity (Fig. 2D).
3.4. Inhibition of ABCA1 with glyburide reverses the PLTP-mediated
increase in nuclear pSTAT3Tyr705 levels in THP1 and primary human
monocyte-derived macrophages
To conﬁrm that the observed increase in active STAT3 in the
nucleus is dependent on ABCA1, we inhibited ABCA1with glyburide, a
commonly used ABCA1 chemical inhibitor [30–33]. Glyburide re-versed the PLTP-mediated increase in nuclear pSTATTyr705 in TNFα-
stimulated, differentiated THP1 cells (Fig. 3A) and human monocyte-
derived macrophages (Fig. 3B). Similar effects were observed using
wild-type PLTP ormutant PLTPwithout phospholipid transfer activity,
PLTPM159E (Fig. 3B), conﬁrming previously published ﬁndings that
both wild-type and mutant PLTP interact with ABCA1 [22], and
indicating that inhibition of ABCA1 reverses the PLTP-dependent
induction of pSTAT3Tyr705. Furthermore, glyburide inhibited the PLTP-
dependent reduction of cytokines, such as MIP1α and IL-1β, in
conditioned media of THP1 macrophages (Fig. 3C).
3.5. ABCA1 RNA inhibition attenuates PLTP-mediated activation of STAT3
in THP1 cells
Chemical inhibition data were further conﬁrmed using ABCA1
RNA inhibition. PLTP increased levels of pSTAT3Tyr705 in cells
transduced with mock viral construct, but not in cells with ABCA1
RNAi (Fig. 4). Spinoculation procedure did not interfere with PLTP-
mediated increase in pSTAT3Tyr705 (not shown).
3.6. PLTP reduces levels of secreted pro-inﬂammatory cytokines in THP1
cells and human monocyte-derived macrophages
Activation of STAT3 in macrophages inhibits transcription of pro-
inﬂammatory cytokines [34]. Therefore, we tested levels of secreted
cytokines in conditionedmedia of LPS-, TNFα- and IFNγ-activated THP1
macrophages in the presence or absence of PLTP, using both pre-
incubation and co-incubation modalities. PLTP signiﬁcantly reduced
levels of pro-inﬂammatory cytokines under both experimental condi-
tions (Fig. 5). These ﬁndings were conﬁrmed in conditioned media
derived from human monocyte-derived macrophages by blotting for
selected pro-inﬂammatory cytokines (see Fig. 3C for an example).
Consequently, PLTP signiﬁcantly reduces secretion of pro-inﬂammatory
cytokines in macrophages. Interestingly, exposure of cells to PLTP prior
to exposure to LPS, TNFα or IFNγ was sufﬁcient to reduce secretion of
pro-inﬂammatory cytokines, supporting our hypothesis that PLTP-
mediated regulation of signal transduction may be involved.
3.7. PLTP reduces nuclear levels of active NFκB p65 in THP1 cells and
human monocyte-derived macrophages
NFκB-mediated regulation of the inﬂammatory response in
macrophages is one of the mainmechanisms involved in the initiation
of the inﬂammatory response [35]. Thus, we also tested the effect of
PLTP on NFκB in human monocyte-derived macrophages and
differentiated THP1 cells. Addition of PLTP to cells signiﬁcantly
reduced levels of active p65, phospho-p65Ser536, in nuclei of human
monocyte-derived and THP1 macrophages, as well as in cells
stimulated with TNFα (Fig. 6).
4. Discussion
In our recent studies we identiﬁed proteins associatedwith PLTP in
human plasma, and reported that the majority of the PLTP-associated
proteins play a role in the innate immunity and the inﬂammatory
response [36]. We have previously shown that PLTP binds, transfers,
and neutralizes LPS, but does not present it to CD14 [1,26]. These
observations have been conﬁrmed by in vivo studies, which show that
PLTP is critical for survival in endotoxemia, as PLTP deﬁciency
enhanced LPS effects and caused signiﬁcant mortality [37]. In severe
endotoxemia, PLTP−/− mice had signiﬁcantly higher levels of pro-
inﬂammatory cytokines in plasma and tissues, and isolated spleno-
cytes from PLTP−/− mice exposed to LPS had an enhanced
inﬂammatory response and higher rates of cell death compared to
those isolated from WT mice [37]. These data are in line with clinical
observations that PLTP activity is increased in patients with bacterial
TNFα (10 ng/ml)     +      +      +       +     +      +      +     + 
PLTP (5 µg/ml)     -       -       +       +     -       -       +     + 
Glyburide (2.5 µM)     -       -       -        -      +      +      +     + 
TNFα (10 ng/ml)     +      +      +      +      +      + 
PLTP (5 µg/ml)     -     WT     -    WT     M     M 
Glyburide (2.5 µM)     -       -       +      +      -       + 
TNFα (10 ng/ml)     +      +       +      +     
PLTP (5 µg/ml)     -       +       -       + 










Fig. 3. PLTP-mediated increase in nuclear pSTAT3Tyr705 is reversed in the presence of the ABCA1 inhibitor, glyburide. A) Nuclear pSTAT3Tyr705 in PMA-differentiated THP1 cells
incubated with TNFα (10 ng/ml) in the presence or absence of glyburide (2.5 μM) and/or PLTP (5 μg/ml). B) Nuclear pSTAT3Tyr705 in human monocyte-derived macrophages
incubated without or with TNFα (10 ng/ml), PLTP WT or mutant PLTP without lipid transfer activity (PLTPM159E; 5 μg/ml), and glyburide (2.5 μM). C) Glyburide counters PLTP-
mediated reduction in levels of secreted pro-inﬂammatory cytokines in conditioned media of human monocyte-derived macrophages. The amount of conditioned medium used in
Western analyses was standardized based on total cell protein.
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change that is vital for survival [3,38]. Moreover, these ﬁndings
unequivocally conﬁrm that the role of PLTP in acute bacterial infection
is anti-inﬂammatory, and critical for a successful resolution of the
inﬂammatory processes and survival.Fig. 4. ABCA1 RNA inhibition counters PLTP-mediated increase in levels of pSTAT3Tyr705 in T
ABCA1 shRNA constructs. Following successful transduction by spinoculation, cells were se
ABCA1 in cells transduced with mock and ABCA1 shRNA construct TRCN0000029089 (1). B)
3 h. Nuclear proteins were isolated using NE-PER and resolved by SDS-PAGE and blotted usFindings that the increase of PLTP activity in chronic periodontal
disease is associated with a reduction in the periodontal tissue
damage suggest that PLTP activity plays an important role in the
resolution of the inﬂammatory process in chronic inﬂammatory
diseases [39]. Hence, the observed increases in PLTP levels and activityHP1 cells. THP1 cells were transduced with viral vectors containing control (Mock) or
lected using puromycin (0.6 μg/ml) and differentiated with PMA for 72 h. A) Levels of
THP1 macrophages were then incubated without (control) or with rPLTP (5 μg/ml) for
ing antibodies against TBP (loading control) and pSTAT3Tyr705.
Fig. 5. PLTP reduces secretion of pro-inﬂammatory cytokines by THP1 macrophages. A) Co-incubation of PLTP and lipopolysaccharides (LPS) reduces levels of cytokines in
conditioned media of THP1 cells. Differentiated THP1 cells were incubated with PLTP (5 μg/ml) and LPS (100 ng/ml) for 6 h. Cytokines in conditioned media were measured using
Bio-Rad MultiPlex plates. B) Pre-incubation of THP1 macrophages with PLTP signiﬁcantly reduced LPS-induced secretion of pro-inﬂammatory molecules. THP1 macrophages were
pre-incubated with PLTP (5 μg/ml) for 4 h, extensively washed and then exposed to LPS (100 ng/ml) for 4 h. Cytokines in conditioned media were measured utilizing Bio-Rad
MultiPlex plates. C) PLTP reduces levels of cytokines in conditioned media of THP1 cells incubated with interferon gamma (IFNγ). Conditioned media of THP1 cells incubated with
IFNγ (100 ng/ml) with or without PLTP (5 μg/ml) were analyzed for MIP1α, TNFα and IL-6. Cytokines were measured using Bio-Rad MultiPlex plates or R&D Systems ELISA kit (for
IL-6). D) PLTP reduces levels of cytokines in THP1 conditioned media of cells incubated with tumor necrosis factor α (TNFα). Conditioned media of THP1 cells incubated with TNFα
(10 ng/ml) with or without PLTP (5 μg/ml) were analyzed for IL-6, GM-CSF and IFNγ. All presented data are representative of at least three separate experiments, and are expressed
as mean±SD.
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protective or compensatory mechanism that limits tissue and organ
damage induced by the inﬂammatory response. This idea is further
supported by the fact that reduction of PLTP activity in multiple
sclerosis is associated with active disease, while measures of recovery
correlate with an increase in PLTP activity [16]. Additionally, reduced
plasma PLTP levels and activity have been reported as a risk factor for
peripheral artery disease, which has a signiﬁcant inﬂammatorycomponent [13]. These ﬁndings support the idea that PLTP has an
anti-inﬂammatory role in both acute and chronic inﬂammatory
diseases.
Previously published studies suggest that macrophage PLTP plays
an anti-atherogenic role [19,20]. However, different results were also
reported using the same mouse model under somewhat different
conditions [40]. The inﬂammatory component of the atherogenic
process has long been recognized as one of the most important
TNFα (10 ng/ml) - - + +





Fig. 6. PLTP reduces levels of p65 phosphorylated at serine 536 in nuclei of macrophages
incubated with TNFα. A) PLTP reduces levels of p65 phosphorylated at serine 536 in
nuclei of differentiated THP1 cells incubated with TNFα. Differentiated THP1 cells were
incubated alone (control), with PLTP (5 μg/ml), TNFα (10 ng/ml), or TNFα and PLTP
together for 24 h. Nuclear proteins were isolated, resolved on SDS-PAGE, transferred,
and blotted, employing antibodies against phospho-p65 Ser536. TATA-binding protein
(TBP) was used as loading control. Resulting blots were scanned, evaluated by
densitometry, and adjusted for TBP. Bars represent mean, SD. B) Human monocyte-
derived macrophages were incubated with or without TNFα and PLTP, and levels of
nuclear NFκB p65 phosphorylated at serine 536 were evaluated by Western blotting.
TBP was used as loading control.
1923S. Vuletic et al. / Biochimica et Biophysica Acta 1813 (2011) 1917–1924pathological processes contributing to the development of athero-
sclerosis [41–44]. Due to the pivotal role macrophages play in
inﬂammation, determining whether PLTP affects macrophages in a
pro- or anti-inﬂammatory manner is relevant for the overall
understanding of its physiological and pathophysiological roles.
Findings reported in this study strongly suggest that PLTP induces
an anti-inﬂammatory response through activation of the ABCA1/
STAT3 pathway.
Recent studies identiﬁed ABCA1 as one of the critical intersections
in the regulation of inﬂammation and atherosclerosis [45]. PLTP
interacts with ABCA1, stabilizes it, and its interaction with ABCA1
activates JAK2 in a manner similar to apoA-I [21,22]. Tang and
colleagues showed that binding of apoA-I to ABCA1 activates JAK2 and
STAT3, potently preventing LPS-challenged macrophages from induc-
ing the inﬂammatory cytokines, IL-1β, IL-6, and TNF-α [46].
Additionally, a recent study has shown that the ABCA1-dependent
lipid efﬂux plays a role in regulating the lipid raft-mediated activity of
Toll-like receptors (TLR) [47]. Thus, these ﬁndings suggest that ABCA1
in macrophages functions as an anti-inﬂammatory receptor.
Activation of the STAT3 pathway in macrophages has an anti-
inﬂammatory role [34]. The pathway may be physiologically relevant
because the loss of STAT3 in mouse macrophages increases suscep-
tibility to endotoxic shock and promotes chronic enterocolitis,
indicating its importance in protection against both acute and chronic
inﬂammation [48,49]. Moreover, constitutive expression of active
STAT3 in cultured macrophages nearly abolishes inﬂammatory
cytokine induction [34]. Therefore, the PLTP-dependent increase in
nuclear pSTAT3Tyr705, the active form of STAT3, and the concomitant
reduction in secreted pro-inﬂammatory cytokines indicate that PLTP
activates STAT3, thereby inhibiting the transcription of inﬂammatory
cytokines. Our ﬁndings that glyburide abolishes the observed PLTP-
mediated induction of STAT3, which were conﬁrmed by ABCA1 RNA
inhibition experiments, further suggest that PLTP-dependent upregu-
lation of the STAT3 pathway occurs through PLTP's interaction withABCA1. These pivotal new ﬁndings present a possible mechanism that
may be responsible for the observed reduction in atherosclerosis
levels in mice expressing macrophage PLTP [19,20]. Furthermore, our
ﬁndings are in concordance with a study by Wehinger and colleagues
showing that in the presence of toxic lipids, macrophage PLTP does
not induce inﬂammation, but rather shifts the cellular response to
toxic lipids towards apoptosis [6]. Consequently, it is possible that
PLTP acts as a switch between inﬂammatory and apoptotic response
in macrophages, and that its effects depend on the type, and possibly
duration of the stimulus.
Our ﬁndings indicate that the PLTP-mediated anti-inﬂammatory
response related to its interaction with the ABCA1-dependent
activation of the JAK2/STAT3 pathway is not dependent on PLTP
lipid transfer, since both wild type and mutant PLTP (without
phospholipid transfer ability) caused similar pathway activation.
Therefore, the ABCA1-dependent anti-inﬂammatory response is likely
related to the direct interaction between PLTP and ABCA1, in which
PLTP regulates activation of the STAT3 pathway through ligand
binding to the ABCA1 receptor. Furthermore, PLTP reduced levels
of active NFκB in the nuclei of human monocyte-derived and THP1
macrophages, indicating that PLTP acts on at least two differ-
ent pathways. The NFκB activity in macrophages is predominantly
regulated by TLRs, suggesting that the PLTP anti-inﬂammatory
action is exerted through several signal transduction pathways in
macrophages.
4.1. Conclusions
Inmacrophages, PLTP activates the ABCA1/STAT3 anti-inﬂammatory
pathway, as well as reduces activation of NFκB. Further evaluation of
the mechanisms responsible for the observed PLTP-mediated anti-
inﬂammatory response in macrophages is essential for understanding
the roles PLTP plays in inﬂammation, and in diseases with a strong
inﬂammatory component.
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